Spero Therapeutics, Inc. Annual Report: A Plain-English Guide

I’m writing this guide to help you understand how Spero Therapeutics performed this year. My goal is to break down complex financial filings into simple terms to help you decide if this company belongs in your portfolio.

1. What does the company do?

Spero Therapeutics is a biotech company developing new treatments for drug-resistant bacterial infections. Because they don’t sell any products yet, they don’t have regular sales income. Instead, they rely on partnerships to fund the expensive process of testing new drugs.

This year, Spero made a major strategic shift. To save money, they stopped developing their drug SPR206 and slowed work on SPR720. They are now focusing entirely on tebipenem HBr, an oral antibiotic for complicated urinary tract infections. This move is designed to preserve cash and focus all their resources on their most promising project.

2. Financial performance

Spero’s income comes from partnerships, specifically a 2022 deal with GSK. Under this agreement, Spero received $66 million upfront and is eligible for up to $150 million more if they hit specific development and sales goals, plus a percentage of future sales.

This year, Spero reported $14.5 million in revenue, primarily driven by that GSK payment. Meanwhile, their expenses remain high as they fund a large Phase 3 clinical trial. The company spends cash faster than it brings it in, as they prioritize clinical testing over immediate profitability.

3. Major wins and challenges

By focusing exclusively on tebipenem HBr, Spero has extended its cash runway into late 2025. Cutting other projects has successfully lowered their quarterly cash burn.

The company’s future depends almost entirely on the success of this one drug. They are currently running a final-stage trial to prove the drug’s efficacy to the FDA. If the trial fails, Spero lacks other major projects to fall back on, which would likely force them to issue more shares—reducing your ownership percentage—or restructure the business entirely.

4. Financial health

Spero has about $75.8 million in cash and investments. With roughly 57.9 million shares outstanding, they maintain a balance sheet with very little debt. However, they have a history of selling additional shares to raise capital when funds run low. Management acknowledges that they will need more cash or milestone payments from GSK to operate past 2025, making success with their current trial essential for their survival.

5. Key risks

The biggest risk is that the drug fails to receive regulatory approval. The FDA previously rejected tebipenem HBr, citing concerns about the trial design. While Spero is working to address these issues, there is no guarantee the new data will satisfy the FDA.

Furthermore, the company faces "concentration risk." Their entire value is tied to one drug and one partner (GSK). If the partnership ends, Spero loses its primary source of funding and the support needed to bring a drug to market. This is a "win or lose" investment where the company’s future depends entirely on the outcome of their current clinical trial.

Investor Takeaway: Spero Therapeutics is a high-risk, high-reward play. You are essentially betting on the success of a single drug, tebipenem HBr. If you are considering an investment, ask yourself if you are comfortable with a company that has no product revenue and relies entirely on a single clinical trial outcome and a single corporate partnership to survive.